Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Intensivmedizin und Notfallmedizin
Erschienen in: Intensivmedizin und Notfallmedizin 4/2011

01.05.2011 | Leitlinien und Empfehlungen

Deutsch-österreichische S3-Leitlinie „Infarktbedingter kardiogener Schock – Diagnose, Monitoring und Therapie“

verfasst von: -

Erschienen in: Intensivmedizin und Notfallmedizin | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Diese Leitlinie (http://leitlinien.net/) fokussiert ausschließlich auf den infarktbedingten kardiogenen Schock (IkS). Beide Strategien, sowohl die kardiologische als auch die intensivmedizinische, sind zur erfolgreichen Behandlung der Patienten mit IkS essenziell. Dennoch beschäftigen sich sowohl die europäische als auch die amerikanische Herzinfarkt-Leitlinie nahezu ausschließlich mit den kardiologischen Aspekten.

Methoden

In einem nominalen Gruppenprozess der Delegierten der Deutschen und Österreichischen Gesellschaften für Kardiologie, Internistische und Interdisziplinäre Intensivmedizin, Herz- und Thoraxchirurgie, Anästhesiologie sowie Prävention und Rehabilitation wurde unter Leitung der Arbeitsgemeinschaft der medizinisch-wissenschaftlichen Fachgesellschaften (AWMF) die Evidenz zur Diagnose, zum Monitoring und zur Therapie des IkS systematisch gesammelt und – darauf aufbauend – Empfehlungen ausgearbeitet.

Ergebnisse

Es wurden 111 Empfehlungen erarbeitet und – darauf basierend – 7 Algorithmen mit konkreten Anweisungen zum Handlungsablauf. Tabelle 23 fasst einige wesentliche Empfehlungen zusammen.
Fußnoten
1
Die Expertenkommission der Monitoring-Leitlinie für herzchirurgische Patienten [13] empfiehlt die ZVD-Messung trotz der methodenimmanenten Limitationen wegen der größeren Häufigkeit von akuten postoperativen Perikardtamponaden im operativen Setting; hier kann das ZVD-Monitoring zur frühzeitigen Erkennung einer Perikardtamponade beitragen.
 
Literatur
1.
Goldberg RJ, Spencer FA, Gore JM et al (2009) Thirty-Year Trends (1975 to 2005) in the Magnitude of, Management of, and Hospital Death Rates Associated With Cardiogenic Shock in Patients With Acute Myocardial Infarction. A Population-Based Perspective. Circulation 19:112–119 (eLV 1)
2.
Prondzinsky R, Lemm H, Swyter M et al (2010) Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: The prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 38:152–160 (eLV 257)PubMedCrossRef
3.
Adams HA, Baumann G, Cascorbi I et al (2005) Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. Deutscher Ärzte, Köln (eLV 30)
4.
Bassand JP, Hamm CW, Ardissino D et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598–1660 (eLV 32)PubMedCrossRef
5.
Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29:2909–2945 (eLV 34)CrossRef
6.
Thygesen K, Alpert JS, White HD (2007) Universal definition of myocardial infarction. Eur Heart J 28:2525–2538 (eLV 35)PubMedCrossRef
7.
Menon V, White H, LeJemtel T et al (2000) The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 36:1071–1076 (eLV 37)PubMedCrossRef
8.
Reynolds HR, Hochman JS (2008) Cardiogenic shock: current concepts and improving outcomes. Circulation 117:686–697 (eLV 44)PubMedCrossRef
9.
The TRIUMPH-Investigators (2007) Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 297:1657–1666 (eLV 78)CrossRef
10.
Hochman JS, Sleeper LA, Webb JG et al (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 341:625–634 (eLV 15)PubMedCrossRef
11.
Hochman JS, Buller CE, Sleeper LA et al (2000) Cardiogenic shock complicating acute myocardial infarction–etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 36:1063–1070 (eLV 42)PubMedCrossRef
12.
Schummer W (2009) Zentraler Venendruck. Validität, Aussagekraft und korrekte Messung. Anaesthesist 58:499–505 (eLV 49)PubMedCrossRef
13.
Carl M, Alms A, Braun J et al (2007) Hämodynamisches Monitoring und Herz-Kreislauf-Therapie: S3-Leitlinie der Deutschen Gesellschaft für Thorax-, Herz- und Gefäßchirurgie (DGTHG) und der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin (DGAI). Thorac Cardiovasc Surg 55:130–148 (eLV 11)PubMedCrossRef
14.
Mueller HS, Chatterjee K, Davis KB et al (1998) ACC expert consensus document. Present use of bedside right heart catheterization in patients with cardiac disease. American College of Cardiology. J Am Coll Cardiol 32:840–864 (eLV 52)PubMedCrossRef
15.
Binanay C, Califf RM, Hasselblad V et al (2005) Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294:1625–1633 (eLV 53)PubMedCrossRef
16.
Harvey SE, Welch CA, Harrison DA et al (2008) Post hoc insights from PAC-Man–the U.K. pulmonary artery catheter trial. Crit Care Med 36:1714–1721 (eLV 54)PubMedCrossRef
17.
Friesecke S, Heinrich A, Abel P, Felix SB (2009). Comparison of pulmonary artery and aortic transpulmonary thermodilution for monitoring of cardiac output in patients with severe heart failure: validation of a novel method. Crit Care Med 37:119–123 (eLV 58)PubMedCrossRef
18.
Uchino S, Bellomo R, Morimatsu H et al (2006) Pulmonary artery catheter versus pulse contour analysis: a prospective epidemiological study. Crit Care 10:R174 (eLV 59)PubMedCrossRef
19.
Cotter G, Moshkovitz Y, Kaluski E et al (2003) The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail 5:443–451 Editorial: Tan et al: 407–410 (eLV 61)
20.
Fincke R, Hochman JS, Lowe AM et al (2004) Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J Am Coll Cardiol 44:340–348 (eLV 19)PubMedCrossRef
21.
Mendoza DD, Cooper HA, Panza JA (2007) Cardiac power output predicts mortality across a broad spectrum of patients with acute cardiac disease. Am Heart J 153:366–370 (eLV 62)PubMedCrossRef
22.
Russ MA, Prondzinsky R, Carter J M et al (2009) Right ventricular function in patients with myocardial infarction complicated by cardiogenic shock – Improvement with levosimendan. Crit Care Med 37:3017–3023 Letters to the editor: 2010;38(1):342–344 und 2010;38(5):1389–1391 (eLV 63)
23.
Reinhart K, Brunkhorst FM, Bone H-G et al (2010) Prävention, Diagnose, Therapie und Nachsorge der Sepsis. 1. Revision der S-2 k Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI). Intensiv- und Notfallbehandlung 35(2):56–104 (eLV 18)
24.
den Uil CA, Lagrand WK, Ent M van der et al (2010) Impaired microcirculation predicts poor outcome of patients with acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 31:3032–3039 (anstelle eLV 66)CrossRef
25.
Zeller M, Cottin Y, Brindisi MC et al (2004) Impaired fasting glucose and cardiogenic shock in patients with acute myocardial infarction. Eur Heart J 25:308–312 (eLV 77)PubMedCrossRef
26.
Katz JN, Stebbins AL, Alexander JH et al (2009) for the TRIUMPH Investigators. Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery. Am Heart J 158:680–687 (eLV 79)PubMedCrossRef
27.
Hochman JS, Sleeper LA, Webb JG et al (2006) Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 295:2511–2515 (eLV 14)PubMedCrossRef
28.
Webb JG, Sleeper LA, Buller CE et al (2000) Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK Trial Registry. J Am Coll Cardiol 36:1084–1090 (eLV81)PubMedCrossRef
29.
Conde-Vela C, Moreno R, Hernandez R et al (2007) Cardiogenic shock at admission in patients with multivessel disease and acute myocardial infarction treated with percutaneous coronary intervention: Related factors. Int J Cardiol 123:29–33 (eLV 82)PubMedCrossRef
30.
Wong SC, Sanborn T, Sleeper LA et al (2000) Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 36:1077–1083 (eLV 83)PubMedCrossRef
31.
Hochman JS, Sleeper LA, White HD et al (2001) One-year survival following early revascularization for cardiogenic shock. JAMA 285:190–192 (eLV 16)PubMedCrossRef
32.
Sleeper LA, Ramanathan K, Picard MH et al (2005) Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 46:266–273 (eLV 84)PubMedCrossRef
33.
Yip HK, Wu CJ, Chang HW et al (2002) Comparison of primary angioplasty and conservative treatment on short- and long-term outcome in octogenarians or older patients with acute myocardial infarction. Jpn Heart J 43:463–474 (eLV 85)PubMedCrossRef
34.
Lindholm MG, Aldershvile J, Sundgreen C et al (2003) Effect of early revascularisation in cardiogenic shock complicating acute myocardial infarction. A single center experience. Eur J Heart Fail 5:73–79 (eLV 86)PubMedCrossRef
35.
Dauerman HL, Goldberg RJ, Malinski M et al (2001) Outcomes and early revascularization for patients >or = 65 years of age with cardiogenic shock. Am J Cardiol 87:844–848 (eLV 87)PubMedCrossRef
36.
Zeymer U, Vogt A, Zahn R et al (2004) Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Eur Heart J 25:322–328 (eLV 88)PubMedCrossRef
37.
Stone GW, Grines CL, Cox DA et al (2002) Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. N Engl J Med 346:957–966 (eLV 90)PubMedCrossRef
38.
De Luca G, Suryapranata H, Stone GW et al (2008) Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol 126:37–44 (eLV 91)CrossRef
39.
Dauerman HL, Goldberg RJ, White K et al (2002) Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 90:838–842 (eLV 92)PubMedCrossRef
40.
Chan AW, Chew DP, Bhatt DL et al (2002) Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 89:132–136 (eLV 93)PubMedCrossRef
41.
Giri S, Mitchel J, Azar RR et al (2002) Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 89:126–131 (eLV 94)PubMedCrossRef
42.
Serruys PW, Morice MC, Kappetein AP et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360:961–972 (eLV 105)PubMedCrossRef
43.
The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on myocardial revascularization. Eur Heart J doi:10.1093/eurheartj/ehq277 (eLV 101)
44.
Lee SW, Hong MK, Lee CW et al (2004) Early and late clinical outcomes after primary stenting of the unprotected left main coronary artery stenosis in the setting of acute myocardial infarction. Int J Cardiol 97:73–76 (eLV 102)PubMedCrossRef
45.
Jeong MH, Ahn YK, Park JC et al (2001) A case of successful primary coronary intervention for the total occlusion of left main stem with the aid of abciximab. J Korean Med Sci 16:509–511 (eLV 106)PubMed
46.
McArdle H, Bhandari M, Kovac J (2003) Emergency coronary stenting of unprotected critical left main coronary artery stenosis in acute myocardial infarction and cardiogenic shock. Heart 89:e24 (eLV 107)PubMedCrossRef
47.
Lee DW, Garnic JD (2002) Stenting of an unprotected left main coronary artery stenosis in cardiogenic shock and ventricular fibrillation: three-year follow-up. J Invasive Cardiol 14:764–766 (eLV 108)PubMed
48.
Webb JG, Lowe AM, Sanborn TA et al (2003) Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol 42:1380–1386 (eLV)PubMedCrossRef
49.
White HD, Assmann SF, Sanborn TA et al (2005) Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. Circulation 112:1992–2001 (eLV 110)PubMedCrossRef
50.
Burzotta F, Testa L, Giannico F et al (2008) Adjunctive devices in primary or rescue PCI: a meta-analysis of randomized trials. Int J Cardiol 123:313–321 (eLV 111)PubMedCrossRef
51.
Rigattieri S, Di Russo C, Musto C et al (2010) Thrombus aspiration during primary angioplasty for cardiogenic shock. Int J Cardiol 140(1):111–113 (eLV 468, ergänzt)PubMedCrossRef
52.
Shindler DM, Palmeri ST, Antonelli TA et al (2000) Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 36:1097–1103 (eLV 114)PubMedCrossRef
53.
Dzavik V, Sleeper LA, Cocke TP et al (2003) Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J 24:828–837 (eLV 115)PubMedCrossRef
54.
Antoniucci D, Valenti R, Migliorini A et al (2003) Comparison of impact of emergency percutaneous revascularization on outcome of patients >or =75 to those <75 years of age with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 91:1458–61 (eLV 116)PubMedCrossRef
55.
Dauerman HL, Ryan TJ Jr, Piper WD et al (2003) Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol 15:380–384 (eLV 117)PubMed
56.
Wong SC, Sleeper LA, Monrad ES et al (2001) Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from the SHOCK Trial Registry. J Am Coll Cardiol 38:1395–1401 (eLV 118)PubMedCrossRef
57.
Arntz HR, Wenzel V, Dissmann R et al (2007) Out-of-hospital thrombolysis during cardiopulmonary resuscitation in patients with high likelihood of ST-elevation myocardial infarction. Resuscitation 76:180–184 (eLV 119)PubMedCrossRef
58.
Arntz H-R, Bossaert LL, Danchin N, Nikolaou NI (2010) European Resuscitation Council Guidelines for Resuscitation 2010 – Section 5. Initial management of acute coronary syndromes. Resuscitation 81:1353–1363 (eLV 469, ergänzt)PubMedCrossRef
59.
Fibrinolytic Therapy Trialists‘ (FTT) Collaborative Group(1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343:311–322; Erratum:1994; 343:742 (eLV 120)
60.
Bonnefoy E, Lapostolle F, Leizorovicz A et al (2002) Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 360:825–829 (eLV 121)PubMedCrossRef
61.
Kennedy JW (1995) The Relative Merits of Direct Angioplasty versus Intravenous Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction. Am J Ther 2:151–153 (eLV 122)PubMedCrossRef
62.
Levine GN, Hochman JS (1995) Thrombolysis in Acute Myocardial Infarction Complicated by Cardiogenic Shock. J Thromb Thrombolysis 2:11–20 (eLV 123)PubMedCrossRef
63.
Menon V, Hochman JS, Stebbins A et al (2000) Lack of progress in cardiogenic shock: lessons from the GUSTO trials. Eur Heart J 21:1928–1936 (eLV 124)PubMedCrossRef
64.
French JK, Feldman HA, Assmann SF et al (2003) Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. Am Heart J 146:804–810 (eLV 125)PubMedCrossRef
65.
Sanborn TA, Sleeper LA, Bates ER et al (2000) Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 36:1123–1129 (eLV 126)PubMedCrossRef
66.
Barron HV, Every NR, Parsons LS et al (2001) The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 141:933–939 (eLV 127)PubMedCrossRef
67.
Zeymer U, Tebbe U, Essen R et al (1999) Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group. Am Heart J 137:34–38 (eLV 128)PubMedCrossRef
68.
Spohr F, Arntz HR, Bluhmki E et al (2005) International multicentre trial protocol to assess the efficacy and safety of tenecteplase during cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest: the Thrombolysis in Cardiac Arrest (TROICA) Study. Eur J Clin Invest 35:315–323 (eLV 129)PubMedCrossRef
69.
Bottiger BW, Arntz HR, Chamberlain DA et al (2008) Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med 359:2651–2662 (eLV 132)PubMedCrossRef
70.
Boden WE (2002) Is it time to reassess the optimal timing of coronary artery bypass graft surgery following acute myocardial infarction? Am J Cardiol 90:35–38 (eLV 133)PubMedCrossRef
71.
Hochman JS, Sleeper LA, Godfrey E et al (1999) SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK: an international randomized trial of emergency PTCA/CABG-trial design. The SHOCK Trial Study Group. Am Heart J 137:313–321 (eLV 134)PubMedCrossRef
72.
Williams SG, Wright DJ, Tan LB (2000) Management of cardiogenic shock complicating acute myocardial infarction: towards evidence based medical practice. Heart 83:621–626 (eLV 135)PubMedCrossRef
73.
Dawson JT, Hall RJ, Hallman GL, Cooley DA (1974) Mortality in patients undergoing coronary artery bypass surgery after myocardial infarction. Am J Cardiol 33:483–486 (eLV 136)PubMedCrossRef
74.
Chiu FC, Chang SN, Lin JW et al (2009) Coronary artery bypass graft surgery provides better survival in patients with acute coronary syndrome or ST-segment elevation myocardial infarction experiencing cardiogenic shock after percutaneous coronary intervention: A propensity score analysis. J Thorac Cardiovasc Surg 138:1326–1330 (eLV 141)PubMedCrossRef
75.
Hochman JS (2003) Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 107:2998–3002 (eLV 142)PubMedCrossRef
76.
Lee DC, Oz MC, Weinberg AD, Ting W (2003) Appropriate timing of surgical intervention after transmural acute myocardial infarction. J Thorac Cardiovasc Surg 125:115–120 (eLV 139)PubMedCrossRef
77.
Lee DC, Oz MC, Weinberg AD et al (2001) Optimal timing of revascularization: transmural versus nontransmural acute myocardial infarction. Ann Thorac Surg 71:1197–1202 (eLV 143)PubMedCrossRef
78.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group(1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360 (eLV 152)
79.
Roux S, Christeller S, Ludin E (1992) Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 19:671–677 (eLV 153)PubMedCrossRef
80.
(o A) (2001)The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502 (eLV 155)
81.
Steinhubl SR, Berger PB, Mann JT 3rd et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411–2420 (eLV 156)PubMedCrossRef
82.
Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 352:1179–1189 (eLV 157)PubMedCrossRef
83.
Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621 (eLV 158)PubMedCrossRef
84.
Gawaz M, Seyfarth M, Muller I et al (2001) Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol 87:332–336 (eLV 159)PubMedCrossRef
85.
Muller I, Seyfarth M, Rudiger S et al (2001) Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart85:92–93 (eLV 80)
86.
Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–15; Editorial: 2078–2081; Comments: 358(12):1298–1301 (eLV 160)
87.
Antoniucci D, Rodriguez A, Hempel A et al (2003) A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 42:1879–1885 (eLV 161)PubMedCrossRef
88.
Montalescot G, Barragan P, Wittenberg O et al (2001) Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction. N Engl J Med 344:1895–1903 (eLV 162)PubMedCrossRef
89.
Neumann FJ, Blasini R, Schmitt C et al (1998) Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98:2695–2701 (eLV 163)PubMed
90.
Antoniucci D, Valenti R, Migliorini A et al (2002) Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol 90:353–357 (eLV 164)PubMedCrossRef
91.
Reid PR, Gu X, Jamal HH (2003) Abciximab treatment for acute myocardial infarction: mortality in patients with cardiogenic shock. Eur Heart J 25(Suppl):25 (eLV 165)CrossRef
92.
Zeymer U, Tebbe U, Weber M et al (2003) Prospective evaluation of early abciximab and primary percutaneous intervention for patients with ST elevation myocardial infarction complicated by cardiogenic shock: results of the REO-SHOCK trial. J Invasive Cardiol 15:385–389 (eLV 166)PubMed
93.
Narins CR, Hillegass WB Jr, Nelson CL et al (1996) Relation between activated clotting time during angioplasty and abrupt closure. Circulation 93:667–671 (eLV 168)PubMed
94.
Giugliano RP, McCabe CH, Antman EM et al (2001) Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 141:742–750 (eLV 169)PubMedCrossRef
95.
S3-Leitlinie: Prophylaxe der venösen Thromboembolie (VTE). http://​leitlinien.​net (eLV 174)
96.
Priglinger U, Delle-Karth G, Geppert A et al (2003) Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med 31:1405–1409 (eLV 175)PubMedCrossRef
97.
Dorffler-Melly J, Jonge E de, Pont AC et al (2002) Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 359:849–850 (eLV 176)PubMedCrossRef
98.
Jochberger S, Mayr V, Luckner G et al (2005) Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study. Crit Care 9:R541–548 (eLV 177)PubMedCrossRef
99.
Cook D, Attia J, Weaver B et al (2000) Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients. J Crit Care 15:127–132 (eLV 178)PubMedCrossRef
100.
Thackray S, Easthaugh J, Freemantle N, Cleland JGF (2002) The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure–a meta-regression analysis. Eur J Heart Fail 4:515 (eLV 181)PubMedCrossRef
101.
Schwertz H, Muller-Werdan U, Prondzinsky R et al (2004) Katecholamine im kardiogenen Schock: hilfreich, nutzlos oder gefahrlich? Dtsch Med Wochenschr 129:1925–1930 (eLV 182)PubMedCrossRef
102.
Lowes BD, Tsvetkova T, Eichhorn EJ et al (2001) Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 81:141–149 (eLV 184)PubMedCrossRef
103.
Metra M, Nodari S, D*Aloia A et al (2002) Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 40:1248–1258 (eLV 185)PubMedCrossRef
104.
Sakr Y, Reinhart K, Vincent JL et al (2006) Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 34:589–597 (eLV 104)PubMedCrossRef
105.
Annane D, Vignon P, Renault A et al (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370:676–84. Editorial 636–637 (eLV 187)PubMedCrossRef
106.
De Backer D, Biston P, Devriendt J et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779–789 (eLV 188)CrossRef
107.
Delaney A, Bradford C, McCaffrey J et al (2010) Levosimendan for the treatment of acute heart failure: A meta-analysis of randomised controlled trials. Int J Cardiol 138:281–289 (eLV 190)PubMedCrossRef
108.
Rokyta R Jr, Pechman V (2006) The effects of Levosimendan on global haemodynamics in patients with cardiogenic shock. Neuro Endocrinol Lett 27:121–127 (eLV 192)PubMed
109.
Mebazaa A, Nieminen MS, Packer M et al (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297:1883–1891 (eLV 197)PubMedCrossRef
110.
Moiseyev VS, Poder P, Andrejevs N et al (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23:1422–1432 (eLV 193)PubMedCrossRef
111.
Delle-Karth G, Buberl A, Geppert A et al (2003) Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 47:1251–1256 (eLV 198)PubMedCrossRef
112.
Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ et al (2006) Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 8:723–728 (eLV 199)PubMedCrossRef
113.
Christoph A, Prondzinsky R, Russ M et al (2008) Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute Card Care 10:49–57 (eLV 200)PubMedCrossRef
114.
Russ MA, Prondzinsky R, Christoph A et al (2007) Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 35:2732–2739 (eLV 201)PubMedCrossRef
115.
Dominguez-Rodriguez A, Samimi-Fard S, Garcia-Gonzalez MJ, Abreu-Gonzalez P (2008) Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. Int J Cardiol 128:214–217 (eLV 202)PubMedCrossRef
116.
Sonntag S, Sundberg S, Lehtonen LA, Kleber FX (2004) The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 43:2177–2182 (eLV 203)PubMedCrossRef
117.
Samimi-Fard S, Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Abreu-Gonzalez P (2007) Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol (eLV 204)
118.
Morelli A, De Castro S, Teboul J-L et al (2005) Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31:638–644 (eLV 206)PubMedCrossRef
119.
Fuhrmann JT, Schmeisser A, Schulze MR et al (2008) Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 36:2257–2266; Editorial: 2450–2451: Comments: 2009;37(3):1181–1182; Erratum: 2008;36(10):2966 (eLV 20)
120.
Gilbert EM, Hershberger RE, Wiechmann RJ et al (1995) Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest 108:1524–1532 (eLV 207)PubMedCrossRef
121.
Cuffe MS, Califf RM, Adams KF Jr et al (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287:1541–1547 (eLV 208)PubMedCrossRef
122.
Koreny M, Karth GD, Geppert A et al (2002) Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med 112:115–119 (eLV 209)PubMedCrossRef
123.
Felker GM, Benza RL, Chandler AB et al (2003) Heart failure etiology and response to milrinone in decompensated heart failure: Results from the OPTIME-CHF study. J Am Coll Cardiol 41:997–1003 (eLV 210)PubMedCrossRef
124.
Aranda JM Jr, Schofield RS, Pauly DF et al (2003) Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J 145:324–329 (eLV 211)PubMedCrossRef
125.
Schreiber W, Herkner H, Koreny M et al (2002) Predictors of survival in unselected patients with acute myocardial infarction requiring continuous catecholamine support. Resuscitation 55:269–276 (eLV 220)PubMedCrossRef
126.
Benzing G 3rd, Helmsworth JA, Schreiber JT, Kaplan S (1979) Nitroprusside and epinephrine for treatment of low output in children after open-heart surgery. Ann Thorac Surg 27:523–528 (eLV 221)PubMedCrossRef
127.
Lisbon A (2003) Dopexamine, dobutamine, and dopamine increase splanchnic blood flow: what is the evidence? Chest 123:460S–463S (eLV 222)PubMedCrossRef
128.
Capomolla S, Febo O, Opasich C et al (2001) Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail 3:601–610 (eLV 229)PubMedCrossRef
129.
Mullens W, Abrahams Z, Francis GS et al (2008) Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 52:200–207 (eLV 230)PubMedCrossRef
130.
Jain P, Massie BM, Gattis WA et al (2003) Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. Am Heart J 145:S3–S17 (eLV 231)PubMedCrossRef
131.
Gensch C, Hoppe U, Böhm M, Laufs U (2011) Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010. Clin Res Cardiol 100(1):1–9 (eLV 471, ergänzt)PubMedCrossRef
132.
Geppert A, Dorninger A, Delle-Karth G et al (2006) Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 34:2035–2042 (eLV 239)PubMedCrossRef
133.
Kohsaka S, Menon V, Lowe AM et al (2005) Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 165:1643–1650 (eLV 240)PubMedCrossRef
134.
Cotter G, Berger PB (2006) Cardiogenic shock–Beyond the large infarction. Crit Care Med 34:2234–2235 (eLV 241)PubMedCrossRef
135.
Pickkers P, Dormans TPJ, Russel FGM et al (1997) Direct Vascular Effects of Furosemide in Humans. Circulation 96:1847–1852 (eLV 243)PubMed
136.
Johnson W, Omland T, Hall C et al (2002) Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39:1623–1629 (eLV 244)PubMedCrossRef
137.
Cotter G, Metzkor E, Kaluski E et al (1998) Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351:389–393 (eLV 227)PubMedCrossRef
138.
Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388–2442 (eLV 179)PubMedCrossRef
139.
Costanzo MR, Guglin ME, Saltzberg MT et al (2007) For the UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49:675–683 (eLV 402)PubMedCrossRef
140.
Hunt SA, Abraham WT, Chin MH et al (2009) Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119:e391–479 (eLV 246)PubMedCrossRef
141.
Nationale Versorgungsleitlinien „Chronische Herzinsuffizienz“. http://​www.​versorgungsleitl​inien.​de (eLV 470, ergänzt)
142.
Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116:e148–304 (eLV 31)PubMedCrossRef
143.
Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117:296–329 (eLV 33)PubMedCrossRef
144.
Krumholz HM, Anderson JL, Brooks NH et al (2006) ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction). Circulation 113:732–761 (eLV 247)PubMedCrossRef
145.
Werdan K, Ruß M, Buerke M (2011) IABP. In: Tubaro M, Danchin N, Filippatos G, Goldstein P, Vranckx P, Zahger D (eds) ESC textbook of intensive and acute cardiac care. Oxford University Press, Chapter 29 (eLV 471)
146.
Stone GW, Ohman EM, Miller MF et al (2003) Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: The benchmark registry. J Am Coll Cardiol 41:1940–1945 (eLV 251)PubMedCrossRef
147.
Cohen M, Urban P, Christenson JT et al (2003) Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark(R) Registry. Eur Heart J 24:1763–1770 (eLV 252)PubMedCrossRef
148.
Anderson RD, Ohman EM, Holmes DR Jr et al (1997) Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 30:708–715 (eLV 253)PubMedCrossRef
149.
Chen EW, Canto JG, Parsons LS et al (2003) Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation 108:951–957 (eLV 254)PubMedCrossRef
150.
Ohman ME, Nanas J, Stomel RJ et al (2005) Thrombolysis and Counterpulsation to Improve Survival in Myocardial Infarction Complicated by Hypotension and Suspected Cardiogenic Shock or Heart Failure: Results of the TACTICS Trial. J Thromb Thrombolysis 19:33–39 (eLV 255)PubMedCrossRef
151.
Sanborn TA, Sleeper LA, Bates ER et al (2000) Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. J Am Coll Cardiol 36:1123–1129 (eLV 263)PubMedCrossRef
152.
Waksman R, Weiss AT, Gotsman MS, Hasin Y (1993) Intra-aortic balloon counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction. Eur Heart J 14:71–74 (eLV 256)PubMed
153.
Vis MM, Sjauw KD, Schaaf RJ van der et al (2007) Prognostic value of admission hemoglobin levels in ST-segment elevation myocardial infarction patients presenting with cardiogenic shock. Am J Cardiol 99:1201–1202 (eVL 258)PubMedCrossRef
154.
Vis MM, V d Schaaf RJ, Sjauw KD et al (2009) Creatinine clearance is independently associated with one year mortality in a primary PCI cohort with cardiogenic shock. Acute Card Care 11:107–112 (eLV 259)PubMedCrossRef
155.
Sjauw KD, Engstrom AE, Vis MM et al (2009) A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J 30:459–468 (eLV 260)PubMedCrossRef
156.
Farto e Abreu P, Thomas B, Loureiro J et al (2002) Inter-hospital transfer of critically-ill patients for urgent cardiac surgery after placement of an intra-aortic balloon pump. Rev Port Cardiol 10:1115–1123 (eLV 261)
157.
Kovack PJ, Rasak MA, Bates ER et al (1997) Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock. J Am Coll Cardiol 29:1454–1458 (eLV 262)PubMedCrossRef
158.
Bur A, Bayegan K, Holzer M et al (2002) Intra-aortic balloon counterpulsation in the emergency department: a 7-year review and analysis of predictors of survival. Resuscitation 53:259–264 (eLV 248)PubMedCrossRef
159.
Grapow MT, Todorov A, Bernet F, Zerkowski HR (2003) Ambulante Langzeitbetreuung mit einem Linksherzunterstutzungssystem. Eine zeitgemasse Modalitat in der Behandlung der terminalen Herzinsuffizienz. Swiss Surg 9:27–30 (eLV 268)PubMedCrossRef
160.
Dembitsky WP, Moore CH, Holman WL et al (1992) Successful mechanical circulatory support for noncoronary shock. J Heart Lung Transplant 11:129–135 (eLV 269)PubMed
161.
Holman WL, Bourge RC, Kirklin JK (1991) Case report: circulatory support for seventy days with resolution of acute heart failure. J Thorac Cardiovasc Surg 102:932–934 (eLV 270)PubMed
162.
Farrar DJ, Chow E, Compton PG et al (1991) Effects of acute right ventricular ischemia on ventricular interactions during prosthetic left ventricular support. J Thorac Cardiovasc Surg 102:588–595 (eLV 271)PubMed
163.
Reinlib L, Abraham W (2003) Recovery from heart failure with circulatory assist: a working group of the National Heart, Lung, and Blood Institute. J Card Fail 9:459–463 (eLV 272)PubMedCrossRef
164.
Seyfarth M, Sibbing D, Bauer I et al (2008) A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 52:1584–1588 (eLV 289)PubMedCrossRef
165.
Combes A, Leprince P, Luyt CE et al (2008) Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med 36:1404–1411 (eLV 291)PubMedCrossRef
166.
Thiele H, Lauer B, Hambrecht R, Boudriot E et al (2001) Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 104:2917–2922 (eLV 287)PubMedCrossRef
167.
Cheng JM, den Uil CA, Hoeks SE et al (2009) Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J 30:2102–2108 (eLV 295)PubMedCrossRef
168.
Pfisterer M (2003) Right ventricular involvement in myocardial infarction and cardiogenic shock. Lancet 362:392–394 (eLV 299)PubMedCrossRef
169.
Hochman JS, Boland J, Sleeper LA et al (1995) Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation 91:873–881 (eLV 304)PubMed
170.
Jacobs AK, Leopold JA, Bates E et al (2003) Cardiogenic shock caused by right ventricular infarction: A report from the SHOCK registry. J Am Coll Cardiol 41:1273–1279 (eLV 305)PubMedCrossRef
171.
Goldstein JA (2002) Pathophysiology and management of right heart ischemia. J Am Coll Cardiol 40:841–853 (eLV 306)PubMedCrossRef
172.
Urban P, Stauffer JC, Bleed D et al (1999) A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J 20:1030–1038 (eLV 307)PubMedCrossRef
173.
Novak PG, Davies C, Gin KG (1999) Survey of British Columbia cardiologists‘ and emergency physicians‘ practice of using nonstandard ECG leads (V4R to V6R and V7 to V9) in the diagnosis and treatment of acute myocardial infarction. Can J Cardiol 15:967–972 (eLV 308)PubMed
174.
Zehender M, Kasper W, Kauder E et al (1993) Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 328:981–988 (eLV 300)PubMedCrossRef
175.
Bueno H, Lopez-Palop R, Perez-David E et al (1998) Combined effect of age and right ventricular involvement on acute inferior myocardial infarction prognosis. Circulation 98:1714–1720 (eLV 309)PubMed
176.
Bowers TR, O’Neill WW, Grines C et al (1998) Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J Med 338:933–940 (eLV 310)PubMedCrossRef
177.
Gumina RJ, Wright RS, Kopecky SL et al (2002) Strong predictive value of TIMI risk score analysis for in-hospital and long-term survival of patients with right ventricular infarction. Eur Heart J 23:1678–1683 (eLV 311)PubMed
178.
Pintaric H, Nikolic-Heitzler V, Mihatov S et al (2001) Dominant right ventricular infarction: is angioplasty the optimal therapeutic approach? Acta Med Austriaca 28:129–134 (eLV 312)PubMedCrossRef
179.
Brodie BR, Stuckey TD, Hansen C et al (2007) Comparison of Late Survival in Patients With Cardiogenic Shock Due to Right Ventricular Infarction Versus Left Ventricular Pump Failure Following Primary Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction. Am J Cardiol 99:431–435 (eLV 313)PubMedCrossRef
180.
Hamon M, Agostini D, Le Page O et al (2008) Prognostic impact of right ventricular involvement in patients with acute myocardial infarction: meta-analysis. Crit Care Med 36:2023–2033 (eLV 303)PubMedCrossRef
181.
Goldstein JA (1998) Right heart ischemia: pathophysiology, natural history, and clinical management. Prog Cardiovasc Dis 40:325–341 (eLV 297)PubMedCrossRef
182.
Haji SA, Movahed A (2000) Right ventricular infarction–diagnosis and treatment. Clin Cardiol 23:473–482 (eLV 298)PubMedCrossRef
183.
O’Rourke RA, Dell’Italia LJ (2004) Diagnosis and management of right ventricular myocardial infarction. Curr Probl Cardiol 29:6–47 (eLV 314)CrossRef
184.
Goldstein JA (2003) Right versus left ventricular shock: A tale of two ventricles. J Am Coll Cardiol 41:1280–1282 (eLV 315)PubMedCrossRef
185.
Yoshino H, Udagawa H, Shimizu H et al (1998) ST-segment elevation in right precordial leads implies depressed right ventricular function after acute inferior myocardial infarction. Am Heart J 135:689–695 (eLV 316)PubMedCrossRef
186.
Jacobs AK, Leopold JA, Bates E et al (2003) Cardiogenic shock caused by right ventricular infarction: A report from the SHOCK registry. J Am Coll Cardiol 41:1273–1279 (eLV 317)PubMedCrossRef
187.
Pinsky MR (2000) Heart – lung interaction. In: Grenvic A: Textbook of critical care. 4th edn. WB Saunders, Philadelphia, pp 1204–1221 (eLV 318)
188.
Cleland JG, Swedberg K, Follath F et al (2003) The EuroHeart Failure survey programme– a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24:442–463 (eLV 319)PubMedCrossRef
189.
Benza RL, Tallaj JA, Felker GM et al (2004) The impact of arrhythmias in acute heart failure. J Card Fail 10:279–284 (eLV 324)PubMedCrossRef
190.
Swart G, Brady WJ Jr, DeBehnke DJ et al (1999) Acute myocardial infarction complicated by hemodynamically unstable bradyarrhythmia: prehospital and ED treatment with atropine. Am J Emerg Med 17:647–652 (eLV 326)PubMedCrossRef
191.
Trappe H-J (2009) Vorhofflimmern – Strategien für die Intensiv- und Notfallmedizin. Intensivmed Notfallmed 46:68–74 (eLV 328)CrossRef
192.
Nolan JP, Soar J, Zideman DA et al (2010) on behalf of the ERC Guidelines Writing Group. European Resuscitation Council Guidelines for Resuscitation 2010 -Section 1. Executive summary. Resuscitation 81:1219–1276PubMedCrossRef
193.
Nolan JP, Soar J (2010) Postresuscitation care: entering a new era. Curr Opin Crit Care 16:216–222 (eLV 472)PubMedCrossRef
194.
Garot P, Lefevre T, Eltchaninoff H et al (2007) Six-month outcome of emergency percutaneous coronary intervention in resuscitated patients after cardiac arrest complicating ST-elevation myocardial infarction. Circulation 115:1354–1362 (eLV 338)PubMedCrossRef
195.
Wolfrum S, Pierau C, Radke PW et al (2008) Mild therapeutic hypothermia in patients after out-of-hospital cardiac arrest due to acute ST-segment elevation myocardial infarction undergoing immediate percutaneous coronary intervention. Crit Care Med 36:1780–1786 (3LV 339)PubMedCrossRef
196.
Noc M, Radsel P (2008) Urgent invasive coronary strategy in patients with sudden cardiac arrest. Curr Opin Crit Care 14:287–291 (eLV 340)PubMedCrossRef
197.
Eisenburger P (2009) Der reanimierte Patient mit akutem Herzinfarkt – Fibrinolyse oder Herzkatheter? Intensivmed 46:61–67 (eLV 341)CrossRef
198.
Hovdenes J, Laake JH, Aaberge L et al (2007) Therapeutic hypothermia after out-of-hospital cardiac arrest: experiences with patients treated with percutaneous coronary intervention and cardiogenic shock. Acta Anaesthesiol Scand 51:137–142 (eLV 343)PubMedCrossRef
199.
Sagalyn E, Band RA, Gaieski DF, Abella BS (2009) Therapeutic hypothermia after cardiac arrest in clinical practice: review and compilation of recent experiences. Crit Care Med 37:S223–S226 (eVL 348)PubMedCrossRef
200.
Pechlaner C, Joannidis M (2009) Therapeutische Hypothermie – Aktuelle Einsatzmöglichkeiten und aktuelles Vorgehen. Intensivmed 46:211–219 (eLV 347)CrossRef
201.
Weisser J, Martin J, Bisping E et al (2001) Influence of mild hypothermia on myocardial contractility and circulatory function. Basic Res Cardiol 96:198–205 (eLV 349)PubMedCrossRef
202.
Schmidt-Schweda S, Ohler A, Grothe A, Pieske B (2004) Cool-Shock I Study: Mild hypothermia as positive inotropic intervention in cardiogenic shock. Circulation 110:A1639 (eLV 350)
203.
Parham W, Edelstein K, Unger B, Mooney M (2009) Therapeutic hypothermia for acute myocardial infarction: past, present, and future. Crit Care Med 37:S234–S237 (eLV 351)PubMedCrossRef
204.
Skulec R, Kovarnik T, Dostalova G et al (2008) Induction of mild hypothermia in cardiac arrest survivors presenting with cardiogenic shock syndrome. Acta Anaesthesiol Scand 52:188–194 (eLV 352)PubMedCrossRef
205.
Cerin G, Di Donato M, Dimulescu D et al (2003) Surgical treatment of ventricular septal defect complicating acute myocardial infarction. Experience of a north Italian referral hospital. Cardiovasc Surg 11:149–154 (eLV 355)PubMedCrossRef
206.
Deja MA, Szostek J, Widenka K et al (2000) Post infarction ventricular septal defect – can we do better? Eur J Cardiothorac Surg 18:194–201 (eLV 356)PubMedCrossRef
207.
Gold HK, Leinbach RC, Sanders CA et al (1973) Intraaortic balloon pumping for ventricular septal defect or mitral regurgitation complicating acute myocardial infarction. Circulation 47:1191–1196 (eLV 357)PubMed
208.
Cox FF, Morshuis WJ, Plokker HW et al (1996) Early mortality after surgical repair of postinfarction ventricular septal rupture: importance of rupture location. Ann Thorac Surg 61:1752–1757; discussion 1757–1758 (eLV 358)PubMedCrossRef
209.
Barker TA, Ramnarine IR, Woo EB et al (2003) Repair of post-infarct ventricular septal defect with or without coronary artery bypass grafting in the northwest of England: a 5-year multi-institutional experience. Eur J Cardiothorac Surg 24:940–946 (eLV 359)PubMedCrossRef
210.
Holzer R, Balzer D, Amin Z et al (2004) Transcatheter closure of postinfarction ventricular septal defects using the new Amplatzer muscular VSD occluder: Results of a U.S. Registry. Catheter Cardiovasc Interv 61:196–201 (eLV 360)PubMedCrossRef
211.
Szkutnik M, Bialkowski J, Kusa J et al (2003) Postinfarction ventricular septal defect closure with Amplatzer occluders. Eur J Cardiothorac Surg 23:323–327 (eLV 361)PubMedCrossRef
212.
Ahmed J, Ruygrok PN, Wilson NJ et al (2008) Percutaneous closure of post-myocardial infarction ventricular septal defects: a single centre experience. Heart Lung Circ 17:119–123 (eLV 362)PubMedCrossRef
213.
Thiele H, Kaulfersch C, Daehnert I et al (2009) Immediate primary transcatheter closure of postinfarction ventricular septal defects. Eur Heart J 30:81–88 (eLV 363)PubMedCrossRef
214.
Di Summa M, Actis Dato GM, Centofanti P et al (1997) Ventricular septal rupture after a myocardial infarction: clinical features and long term survival. J Cardiovasc Surg (Torino) 38:589–593 (eLV 265)
215.
Mark B, Zahn R, Donges K et al (2000) Current use and outcomes of intraaortic balloon counterpulsation in routine cardiology. Med Klin (Munich) 95:429–434 (eLV 264)
216.
Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10:933–989 (eLV 364)PubMedCrossRef
217.
Thompson CR, Buller CE, Sleeper LA et al (2000) Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we use emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 36:1104–1109 (eLV 365)PubMedCrossRef
218.
Moosvi AR, Khaja F, Villanueva L et al (1992) Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 19:907–914 (eLV 366)PubMedCrossRef
219.
Beranek JT (2002) Pathogenesis of postinfarction free wall rupture. Int J Cardiol 84:91–92 (eLV 367)PubMedCrossRef
220.
Blinc A, Noc M, Pohar B et al (1996) Subacute rupture of the left ventricular free wall after acute myocardial infarction. Three cases of long-term survival without emergency surgical repair. Chest 109:565–567 (eLV 368)PubMedCrossRef
221.
Figueras J, Cortadellas J, Calvo F, Soler-Soler J (1998) Relevance of delayed hospital admission on development of cardiac rupture during acute myocardial infarction: study in 225 patients with free wall, septal or papillary muscle rupture. J Am Coll Cardiol 32:135–139 (eLV 369)PubMedCrossRef
222.
Lengyel M, Pal M (1996) Long-term survival of post-infarction free wall rupture without operation. Eur Heart J 17:1769–1770 (eLV 370)PubMed
223.
Tavakoli R, Weber A, Brunner-La Rocca H et al (2002) Results of surgery for irreversible moderate to severe mitral valve regurgitation secondary to myocardial infarction. Eur J Cardiothorac Surg 21:818–824 (eLV 371)PubMedCrossRef
224.
Tavakoli R, Weber A, Vogt P et al (2002) Surgical management of acute mitral valve regurgitation due to post-infarction papillary muscle rupture. J Heart Valve Dis 11:20–25; discussion 26 (eLV 371)PubMed
225.
Pellizzon GG, Grines CL, Cox DA et al (2004) Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J Am Coll Cardiol 43:1368–1374 (eLV 373)PubMedCrossRef
226.
Baue AE, Faist E, Fry DE (2000) Multiple organ failure – pathophysiology, prevention and therapy. Springer, Berlin, Heidelberg, New York (eLV 374)
227.
Müller-Werdan U, Reith S, Werdan K (2011) Multiorgandysfunktionssyndrom (MODS). In: Erdmann E (Hrsg) Klinische Kardiologie. Springer Medizin Verlag Heidelberg, 6. Aufl. 2006;384–398. Siehe auch 7. Aufl. (eLV 375)
228.
Werdan K, Hettwer S, Bubel S et al (2009) Septischer Kreislaufschock und septische Kardiomyopathie. Internist (Berl) 50:799–809 (eLV 41)
229.
Peters J et al (2001) Hemodynamic effects of increased intrathoracic pressure. In: Vincent J-L, Suter PM (Hrsg) Cardiopulmonary interactions in acute respiratory failure (Update in intensive care and emergency medicine, vol 2) Springer, Berlin Heidelberg New York, S 120–135 (eLV 376)
230.
Seige M, Werdan K, Prondzinsky R (2001) Beatmung bei Herzkranken. Intensivmed Notfallmed 38:299–313 (eLV 384)CrossRef
231.
Lesage A, Ramakers M, Daubin C et al (2004) Complicated acute myocardial infarction requiring mechanical ventilation in the intensive care unit: prognostic factors of clinical outcome in a series of 157 patients. Crit Care Med 32:100–105 (eLV 389)PubMedCrossRef
232.
Schönhofer B, Kuhlen R, Neumann P, Westhoff M, Berndt C, Sitter H(2008) S3-Leitlinie: Nichtinvasive Beatmung als Therapie der akuten respiratorischen Insuffizienz. Klinische Leitlinie Nichtinvasive Beatmung bei akuter respiratorischer Insuffizienz. http://​leitlinien.​net/​.​ Dtsch Arztebl 105(24):424–433 (eLV 391)
233.
Gajic O, Dara SI, Mendez JL et al (2004) Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med 32:1817–1824 (eLV 392)PubMedCrossRef
234.
Lipiner-Friedman D, Sprung CL, Laterre PF et al (2007) Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med 35:1012–1018 (eLV 393)PubMedCrossRef
235.
Jabre P, Combes X, Lapostolle F et al (2009) Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 374:293–300 (eLV 394)PubMedCrossRef
236.
Martin J, Bäsell K, Bürkle H et al (2005) Analgesie und Sedierung in der Intensivmedizin. S2-Leitlinie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin. Anaesthesiol Intensivmed 46(Suppl 1):S1–S20 (eLV 395)
237.
Ely EW, Truman B, Shintani A et al (2003) Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 289:2983–2991 (eLV 396)PubMedCrossRef
238.
Sessler CN, Gosnell MS, Grap MJ et al (2002) The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 166:1338–1344 (eLV 397)PubMedCrossRef
239.
240.
Kuhlen R, Roissant R (1999) Entwöhnung von der Beatmung: Standardisierte Protokolle erfolgreicher als Ärzte? Intensivmed Notfallmed 36:415–416 (eLV 399)CrossRef
241.
Lemaire F, Teboul JL, Cinotti L et al (1988) Acute left ventricular dysfunction during unsuccessful weaning from mechanical ventilation. Anesthesiology 69:171–179 (eLV 400)PubMedCrossRef
242.
Hilge R, Fischereder M (2009) Was gibt’s Neues in der mechanischen Therapie des akuten Nierenversagens? Intensiv- und Notfallbehandlung 34:94–103 (eLV 401)
243.
Angstwurm MWA, Gärtner R (2005) Endokrine Störungen und Spurenelementdefizienzen. In: Werdan K, Schuster H-P, Müller-Werdan U (Hrsg) Sepsis und MODS, 4. Aufl. Springer Medizin Heidelberg, S 473–483 (eLV 403)
244.
Kilger E, Weis F, Briegel J et al (2003) Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 31:1068–1074 (eLV 404)PubMedCrossRef
245.
Berghe G van den, Wouters P, Weekers F et al (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367 (eLV 405)PubMedCrossRef
246.
Mohr M, Englisch L, Roth A et al (1997) Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 23:1144–1149 (eLV 406)PubMedCrossRef
247.
Schmidt H, Muller-Werdan U, Hoffmann T et al (2002) Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med 33:1994–2002 (eLV 407)CrossRef
248.
Werdan K, Schmidt H, Ebelt H et al (2009) Impaired regulation of cardiac function in sepsis, SIRS, and MODS. Can J Physiol Pharmacol 87:266–274 (eLV 408)PubMedCrossRef
249.
Werdan K, Girndt M, Ebelt H (2011) Monitoring of kidney, liver and other vital organs. In: Tubaro M, Danchin N, Filippatos G, Goldstein P, Vranckx P, Zahger D (eds) ESC Textbook of intensive and acute cardiac care. Oxford University Press, Chapter 17 (eLV 473)
250.
Smet AM de, Kluytmans JA, Cooper BS et al (2009) Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 360:20–31 (eLV 411)PubMedCrossRef
251.
Deutsche Gesellschaft für Ernährungsmedizin(2007) Leitlinie Parenterale Ernährung der DGEM. Aktuel Ernahrungsmed 32:3–6 (eLV 412)CrossRef
252.
Kreymann KG, Berger MM, Deutz NE et al (2006) ESPEN Guidelines on enteral nutrition: intensive care. Clin Nutr 25:210–223 (eLV 413)PubMedCrossRef
253.
Simpson F, Doig GS (2005) Parenteral vs. enteral nutrition in the critically ill patient: a meta-analysis of trials using the intention to treat principle. Intensive Care Med 31:12–23 (eLV 414)PubMedCrossRef
254.
Gramlich L, Kichian K, Pinilla J et al (2004) Does enteral nutrition compared to parenteral nutrition result in better outcomes in critically ill adult patients? A systematic review of the literature. Nutrition 20:843–848 (eLV 415)PubMedCrossRef
255.
Gadek JE, DeMichele SJ, Karlstad MD et al (1999) Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med 27:1409–1420 (eLV 416)PubMedCrossRef
256.
Finfer S, Chittock DR, Su SY et al (2009) Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360:1283–1297 (eLV 421)PubMedCrossRef
257.
Cobb LA, Killip T, Lambrew CT et al (2005) Glucose-insulin-potassium infusion and mortality in the CREATE-ECLA trial. JAMA 293(4):437–446; Letters and authors‘ reply:2005;293(21):2596–2597; Letters and authors‘ reply:2005;293(21):2598. (eLV 26)
258.
Malmberg K, Ryden L, Wedel H et al (2005) Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26:650–661 (eLV 423)PubMedCrossRef
259.
Finney SJ, Zekveld C, Elia A, Evans TW (2003) Glucose control and mortality in critically ill patients. JAMA 290:2041–2047 (eLV 424)PubMedCrossRef
260.
Dandona P, Chaudhuri A, Ghanim H (2009) Acute myocardial infarction, hyperglycemia, and insulin. J Am Coll Cardiol 53:1437–1439 (eLV 427)PubMedCrossRef
261.
Timmer JR, Svilaas T, Ottervanger JP et al (2006) Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II. J Am Coll Cardiol 47:1730–1731 (eLV 428)PubMedCrossRef
262.
Bundesärztekammer(2009) Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Deutscher Ärzteverlag Köln (eLV 440)
263.
Corwin HL, Gettinger A, Pearl RG et al (2002) Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 288:2827–2835 (eLV 432)PubMedCrossRef
264.
Corwin HL, Gettinger A, Fabian TC et al (2007) Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 965–976 (eLV 433)
265.
Koch CG, Li L, Duncan AI et al (2006) Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg 81:1650–1657 (eLV 434)PubMedCrossRef
266.
Kunadian B, Sutton AG, Vijayalakshmi K et al (2007) Early invasive versus conservative treatment in patients with failed fibrinolysis–no late survival benefit: the final analysis of the Middlesbrough Early Revascularisation to Limit Infarction (MERLIN) randomized trial. Am Heart J 153:763–771 (eLV 436)PubMedCrossRef
267.
Malone DL, Poston RS, Hess JR (2006) Blood product transfusion in association with coronary artery bypass grafting: proceed with caution. Crit Care Med 34:1823–1824 (eLV 436)PubMedCrossRef
268.
Hebert PC, Yetisir E, Martin C et al (2001) Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 29:227–234 (eLV 431)PubMedCrossRef
269.
Rao SV, Jollis JG, Harrington RA et al (2004) Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292:1555–1562 (eLV 437)PubMedCrossRef
270.
Murphy GJ, Reeves BC, Rogers CA et al (2007) Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 116:2544–2552 (eLV 438)PubMedCrossRef
271.
Wu WC, Rathore SS, Wang Y et al (2001) Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345:1230–1236 (eLV 439)PubMedCrossRef
272.
Cook D, Crowther M, Meade M et al (2003) Deep venous thrombosis in medical-surgical ICU patients: prevalence, incidence and risk factors. Crit Care 7:P111 (eLV 441)CrossRef
273.
Attia J, Ray JG, Cook DJ et al (2001) Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161:1268–1279 (eLV 443)PubMedCrossRef
274.
Cook DJ, Fuller HD, Guyatt GH et al (1994) Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 330:377–381 (eLV 445)PubMedCrossRef
275.
Cook D, Guyatt G, Marshall J et al (1998) A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 338:791–797 (eLV 446)PubMedCrossRef
276.
Conrad SA, Gabrielli A, Margolis B et al (2005) Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 33:760–765 (eLV 447)PubMedCrossRef
277.
Cooper DJ, Walley KR, Wiggs BR, Russell JA (1990) Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med 112:492–498 (eLV 448)PubMed
278.
Mathieu D, Neviere R, Billard V et al (1991) Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med 19:1352–1356 (eLV 449)PubMedCrossRef
279.
Jaarsma T, Beattie JM, Ryder M et al (2009) Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 11:433–443 (eLV 450)PubMedCrossRef
280.
Sanborn TA, Sleeper LA, Webb JG et al (2003) Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol 42:1373–1379 (eLV 451)PubMedCrossRef
281.
Ammann P, Straumann E, Naegeli B et al (2002) Long-term results after acute percutaneous transluminal coronary angioplasty in acute myocardial infarction and cardiogenic shock. Int J Cardiol 82:127–131 (eLV 452)PubMedCrossRef
282.
Lindholm MG, Kober L, Boesgaard S et al (2003) Cardiogenic shock complicating acute myocardial infarction; prognostic impact of early and late shock development. Eur Heart J 24:258–265 (eLV 10)PubMedCrossRef
283.
Singh M, White J, Hasdai D et al (2007) Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol 50:1752–1758 (eLV 453)PubMedCrossRef
284.
Bjarnason-Wehrens B, Held K, Hoberg E et al (2007) Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislauferkrankungen (DLL-KardReha). Clin Res Cardiol Suppl 2:1–54 (eLV 456)CrossRef
285.
Drazner MH, Rame JE, Stevenson LW, Dries DL (2001) Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 345:574–581 (eLV 27)PubMedCrossRef
286.
Steinbeck G, Andresen D, Seidl K et al (2009) Defibrillator implantation early after myocardial infarction. N Engl J Med 361:1427–1436 (eLV 460)PubMedCrossRef
287.
Hohnloser SH, Kuck KH, Dorian P et al (2004) Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351:2481–2488 (eLV 461)PubMedCrossRef
288.
Georgiopoulou VV, Kalogeropoulos AP, Giamouzis G et al (2009) Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. Circ Heart Fail 2:90–97 (eLV 462)PubMedCrossRef
289.
Bjarnason-Wehrens B, Mayer-Berger W, Meister ER et al (2004) Einsatz von Kraftausdauertraining und Muskelaufbautraining in der kardiologischen Rehabilitation. Empfehlungen der Deutschen Gesellschaft für Prävention und Rehabilitation von Herz-Kreislauferkrankungen e. V. Z Kardiol 93:357–370 (eLV 464)PubMedCrossRef
290.
291.
Stork S, Faller H, Schowalter M et al (2009) Evidenz-basiertes Krankheitsmanagement bei Herzinsuffizienz (HeartNetCare-HF© Würzburg). Dtsch Med Wochenschr 134:773–776 (eLV 466)PubMedCrossRef
292.
Capomolla S, Febo O, Ceresa M et al (2002) Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care. J Am Coll Cardiol 40:1259–1266 (eLV 467)PubMedCrossRef
293.
Jaber S, Jung B, Chanques G et al (2009) Effects of steroids on reintubation and post-extubation stridor in adults: meta-analysis of randomised controlled trials. Crit Care 13:R49 (eLV noch nicht erfasst)PubMedCrossRef
Metadaten
Titel
Deutsch-österreichische S3-Leitlinie „Infarktbedingter kardiogener Schock – Diagnose, Monitoring und Therapie“
verfasst von
-
Publikationsdatum
01.05.2011
Verlag
Springer-Verlag
Erschienen in
Intensivmedizin und Notfallmedizin / Ausgabe 4/2011
Print ISSN: 0175-3851
Elektronische ISSN: 1435-1420
DOI
https://doi.org/10.1007/s00390-011-0284-8

Weitere Artikel der Ausgabe 4/2011

Intensivmedizin und Notfallmedizin 4/2011 Zur Ausgabe

Leitthema

Lungenembolie

Leitthema

Nierenersatztherapie: Wann? Wie? Wie lange?

Leitthema

Therapie des nichtinfarktbedingten kardiogenen Schocks

OriginalPaper

Differenzialdiagnose und Management von Weaningproblemen

Einführung zum Thema

„Facts and Fiction“ in der Intensivmedizin

Leitthema

Intensivtherapie in der Postreanimationsphase

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise